Name: Cymabay Therapeutics, Inc.
Address: 7999 Gateway Blvd Ste 100, Newark, CA, 94560-1144, USA
Telephone: (510) 293-8800

Metabolex discovers and develops novel therapeutics to treat type 2 diabetes and related metabolic disorders. It is our goal to bring to the patient breakthrough medicines that improve quality of life. Our deep understanding of the biology of these diseases has enabled us to build a robust pipeline of proprietary product candidates.

MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR 119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 is a potent GPR 119 agonist that has completed three Phase 1 trials and is currently in Phase 2 testing. In all studies to date, MBX-2982 was rapidly absorbed, lowered glucose excursions, and was well-tolerated with no serious adverse events.

Arhalofenate (MBX-102) is an oral, small-molecule insulin sensitizer that is also a potent uricosuric agent. Research to date suggests that arhalofenate may have efficacy comparable to the currently marketed insulin sensitizers with a superior safety and tolerability profile. Currently marketed sensitizers cause weight gain and edema and carry a black box warning that cautions physicians about the risk of heart failure. Clinical studies to date indicate that arhalofenate, in contrast, does not cause weight gain or edema. Arhalofenate has also shown consistently shown robust uric acid lowering in normal patients and type 2 diabetics.

MBX-8025 is our product candidate for treating mixed dyslipidemia, a group of disorders that includes elevated LDL cholesterol and/or triglycerides, and low levels of HDL cholesterol. We recently completed a thorough Phase 2 proof-of-concept study that showed MBX-8025 effectively addresses each of the lipid abnormalities associated with mixed dyslipidemia and also showed potential efficacy at treating other metabolic disorders.

Our strategy is to discover and develop promising therapies for metabolic diseases to address significant unmet medical needs in large markets, developing them through proof-of-concept studies and then collaborating with companies through late-stage clinical trials and commercialization to maximize the value of our compounds.

To execute our strategy, we have assembled a management team with deep experience in developing promising drugs and technologies, including former executives at Syntex, Roche, Merck, Pfizer and Sugen.

Cymabay Therapeutics, Inc.

Business Info

Contact Business

Company Summary

Similar Businesses Nearby

Competitive Landscape

Payments Accepted

Hours

Photos

Business Credit Report

Facebook

Twitter

Yelp

Customer Resources

Our Company

Our Network

Site Links